PMID- 8241012
OWN - NLM
STAT- MEDLINE
DCOM- 19931227
LR  - 20190914
IS  - 0920-3206 (Print)
IS  - 0920-3206 (Linking)
VI  - 7
IP  - 4
DP  - 1993 Aug
TI  - Risk stratification and prognosis of patients treated with amiodarone for 
      malignant ventricular tachyarrhythmias after myocardial infarction.
PG  - 683-9
AB  - Seventy-seven consecutive patients (mean age 62 years) with episodes of sustained 
      ventricular tachycardia (VT) or ventricular fibrillation (VF) after acute 
      myocardial infarction (AMI) were evaluated to assess the long-term efficacy of 
      first-line amiodarone treatment and to identify clinical and laboratory factors 
      associated with a high risk of death or arrhythmia recurrence. The presenting 
      arrhythmia was VT in 41 cases (53%) and VF in 36 (47%). VT or VF occurred between 
      the 4th and 90th day after AMI in 45 cases (58%) and later (more than 90 days) in 
      the remaining 32 (42%). The mean number of arrhythmic episodes was 4.2. Forty 
      patients (52%) were in New York Heart Association (NYHA) class I or II, and 37 
      (48%) were in class III or IV. Mean left ventricular ejection fraction was 32%; 
      ventricular aneurysm was present in 41 subjects. Most patients had multivessel 
      coronary artery disease. Amiodarone was administered as a first-choice drug in 
      all patients, in combination with other antiarrhythmic drugs in 14. By 
      ventricular stimulation after loading doses of amiodarone, sustained VT was 
      inducible in 46 (62%) and noninducible in 28 (38%). During a mean follow-up of 28 
      months the incidence of cardiac mortality at 1, 3, and 5 years was 21%, 37%, and 
      47%; of sudden death was 7%, 19%, and 23%; of nonfatal VT recurrence was 13%, 
      13%, and 24%, respectively. The overall incidence of amiodarone side effects was 
      35%.2+ was a weak predictor only by univariate analysis (p = 0.05).(ABSTRACT 
      TRUNCATED AT 250 WORDS)
FAU - Proclemer, A
AU  - Proclemer A
AD  - Istituto di Cardiologia, Ospedale S.M. della Misericordia, Udine, Italy.
FAU - Facchin, D
AU  - Facchin D
FAU - Vanuzzo, D
AU  - Vanuzzo D
FAU - Feruglio, G A
AU  - Feruglio GA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Cardiovasc Drugs Ther
JT  - Cardiovascular drugs and therapy
JID - 8712220
RN  - N3RQ532IUT (Amiodarone)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amiodarone/*therapeutic use
MH  - Analysis of Variance
MH  - Angiocardiography
MH  - Electrophysiology
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*complications
MH  - Prognosis
MH  - Recurrence
MH  - Risk
MH  - Tachycardia, Ventricular/*drug therapy/etiology/mortality
MH  - Treatment Outcome
MH  - Ventricular Fibrillation/*drug therapy/etiology/mortality
EDAT- 1993/08/01 00:00
MHDA- 1993/08/01 00:01
CRDT- 1993/08/01 00:00
PHST- 1993/08/01 00:00 [pubmed]
PHST- 1993/08/01 00:01 [medline]
PHST- 1993/08/01 00:00 [entrez]
AID - 10.1007/BF00877822 [doi]
PST - ppublish
SO  - Cardiovasc Drugs Ther. 1993 Aug;7(4):683-9. doi: 10.1007/BF00877822.